The rationale of the protocol is based on the reported beneficiary results of case-patients
by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of
a probable autoimmune predisposition of the disease. The objective of this study is to
clarify the potency of etanercept for the therapy of hidradenitis suppurativa.